In re Thalomid and Revlimid Antitrust Litig., No. 2:14-cv-06997 (D.N.J.) – Hausfeld represents a class of end payors who allege that Celgene engaged in a multi-faceted scheme to maintain its monopoly and interfere with competitors’ efforts to enter the market with generic versions of Thalomid and Revlimid. Plaintiffs allege that Celgene acted to delay the onset of generic competition and charged users billions of dollars for these products.
On March 30, 2020, the parties reached a settlement agreement on behalf of a class of consumers and entities who purchased Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee.
As further detailed in Plaintiffs’ Unopposed Motion for Preliminary Approval, Celgene has agreed to pay $34 million to settle these claims.